Sysmex Journal International

2021Vol.31 No.1


Drug Induced Tubulo-interstitial Nephritis, New Insight for Diagnosis


Yasuhide NISHIO

Department of Internal Medicine, Tokyo Metropolitan Tama Medical Center


In recent years there has been a greater focus on drug-induced tubulointerstitial nephritis. The problem with this disease is that the real situation has not been well understood in spite of an unmistakable increase in incidence in recent years. Its diagnosis is difficult because there are not many symptoms, and many cases are probably being missed. The present situation is that chronic kidney disease (CKD) is induced by continued use of drugs that can cause the condition, and this in turn increases the number of patients who require dialysis. Polypharmacy (the prescription of concurrent use of multiple medications) in an aging society is viewed as a problem to be addressed from the perspective of both the healthcare economy and the adverse reactions. One polypharmacy-related problem that should not be overlooked is drug-induced tubulointerstitial nephritis. Here I shall explain this disease, mainly its background and countermeasures. I shall then give some suggestions about how medical professionals should deal with this disease.


Drug Induced Tubulo-interstitial Nephritis, Proton Pump Inhibitor, Eosinophiluria, Automated Urine Cytometry Analysis


This article is based on current regulatory requirements in Japan. (as of August 2020)
The specifications, performances and functions described here may be different depending on the regions or the countries due to the regulatory affairs, legal matters or local guidelines. For more details, please contact your regional affiliates or distributors.
This article is translated and republished from the Sysmex Journal Web Vol.21 No.2, 2020. (Japanese)